株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

モノクローナル抗体の世界市場:2018年~2022年

Global Monoclonal Antibodies Market 2018-2022

発行 TechNavio (Infiniti Research Ltd.) 商品コード 364925
出版日 ページ情報 英文 115 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.43円で換算しております。
Back to Top
モノクローナル抗体の世界市場:2018年~2022年 Global Monoclonal Antibodies Market 2018-2022
出版日: 2018年12月07日 ページ情報: 英文 115 Pages
概要

世界のモノクローナル抗体市場は、2022年まで、およそ15%のCAGR(複合年間成長率)で拡大すると予測されています。

当レポートでは、世界のモノクローナル抗体市場について調査し、市場の成長見通し、地域別動向、市場の動向と課題、主要ベンダーの競合動向などをまとめています。

第1章 エグゼクティブサマリー

第2章 当レポートの調査範囲

第3章 調査手法

第4章 市場情勢

  • 市場エコシステム
  • 市場の特徴
  • 市場セグメント分析

第5章 パイプライン分析

第6章 市場規模

  • 市場定義
  • 市場規模
  • 市場規模と予測

第7章 ファイブフォース分析

第8章 用途別の市場分類

  • 用途別の分類
  • 用途別の比較
  • 腫瘍学 - 市場規模と予測
  • 免疫学 - 市場規模と予測
  • 血液学 - 市場規模と予測
  • その他 - 市場規模と予測
  • 市場機会:用途別

第9章 モノクローナル抗体の種類別の市場分類

  • モノクローナル抗体の種類別の市場分類
  • マウス抗体
  • ヒト抗体
  • ヒト化抗体
  • キメラ抗体

第10章 顧客情勢

第11章 地域情勢

  • 地理区分
  • 地域比較
  • 南北アメリカ - 市場規模と予測
  • 欧州・中東・アフリカ地域 - 市場規模と予測
  • アジア太平洋地域 - 市場規模と予測
  • 市場機会

第12章 意思決定の枠組み

第13章 市場の成長因子と課題

  • 市場成長因子
  • 市場の課題

第14章 市場動向

第15章 ベンダー情勢

  • 概要
  • 創造的破壊の状況

第16章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • AbbVie
  • Amgen
  • Johnson & Johnson
  • Merck

第17章 付録

  • 略語リスト
図表
  • Exhibit 01: Parent market
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Monoclonal antibodies in the pipeline
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2017
  • Exhibit 08: Validation techniques employed for market sizing 2017
  • Exhibit 09: Global monoclonal antibodies market - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 10: Global monoclonal antibodies market - Year-over-year growth 2018-2022 (%)
  • Exhibit 11: Five forces analysis 2017
  • Exhibit 12: Five forces analysis 2022
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2017
  • Exhibit 19: Global monoclonal antibodies market by application - Market share 2017-2022 (%)
  • Exhibit 20: Comparison by application
  • Exhibit 21: List of monoclonal antibodies approved by FDA/European Medicines Agency post 2015
  • Exhibit 22: Oncology - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 23: Oncology - Year-over-year growth 2018-2022 (%)
  • Exhibit 24: Sales of monoclonal antibodies in oncology ($ mn)
  • Exhibit 25: Immunology - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 26: Sales of monoclonal antibodies for immunology ($ mn)
  • Exhibit 27: Immunology - Year-over-year growth 2018-2022 (%)
  • Exhibit 28: Hematology - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 29: Hematology - Year-over-year growth 2018-2022 (%)
  • Exhibit 30: Others - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 31: Sales of monoclonal antibodies in the others segment ($ mn)
  • Exhibit 32: Others - Year-over-year growth 2018-2022 (%)
  • Exhibit 33: Market opportunity by application
  • Exhibit 34: Customer landscape
  • Exhibit 35: Global monoclonal antibodies market by geography - Market share 2017-2022 (%)
  • Exhibit 36: Regional comparison
  • Exhibit 37: Americas - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 38: Americas - Year-over-year growth 2018-2022 (%)
  • Exhibit 39: Top 3 countries in Americas
  • Exhibit 40: EMEA - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 41: EMEA - Year-over-year growth 2018-2022 (%)
  • Exhibit 42: Top 3 countries in EMEA
  • Exhibit 43: APAC - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 44: APAC - Year-over-year growth 2018-2022 (%)
  • Exhibit 45: Top 3 countries in APAC
  • Exhibit 46: Market opportunity
  • Exhibit 47: Vendor landscape
  • Exhibit 48: Landscape disruption
  • Exhibit 49: Vendor classification
  • Exhibit 50: Market positioning of vendors
  • Exhibit 51: AbbVie: An overview
  • Exhibit 52: AbbVie - Business segments
  • Exhibit 53: AbbVie - Organizational developments
  • Exhibit 54: AbbVie - Geographic focus
  • Exhibit 55: AbbVie - Segment focus
  • Exhibit 56: AbbVie - Key offerings
  • Exhibit 57: Amgen: An overview
  • Exhibit 58: Amgen - Business segments
  • Exhibit 59: Amgen - Organizational developments
  • Exhibit 60: Amgen - Geographic focus
  • Exhibit 61: Amgen - Segment focus
  • Exhibit 62: Amgen - Key offerings
  • Exhibit 63: Johnson & Johnson: An overview
  • Exhibit 64: Johnson & Johnson - Business segments
  • Exhibit 65: Johnson & Johnson - Organizational developments
  • Exhibit 66: Johnson & Johnson - Geographic focus
  • Exhibit 67: Johnson & Johnson - Segment focus
  • Exhibit 68: Johnson & Johnson - Key offerings
  • Exhibit 69: Merck: An overview
  • Exhibit 70: Merck - Business segments
  • Exhibit 71: Merck - Organizational developments
  • Exhibit 72: Merck - Geographic focus
  • Exhibit 73: Merck - Segment focus
  • Exhibit 74: Merck - Key offerings
目次
Product Code: IRTNTR21977

About this market:

Rise in the number of companies venturing into monoclonal antibodies space to drive market growth. To gain profits, the companies are investing huge amounts in the development of monoclonal antibodies. At present, companies are expanding their businesses to increase the development and sales of monoclonal antibodies. Technavio's analysts have predicted that the monoclonal antibodies market will register a CAGR of about 15% by 2022.

Market Overview:

Introduction of low cost biosimilar monoclonal antibodies

The introduction of biosimilars aimed at curbing the increasing year-over-year cost of healthcare and handling the economic pressure from the patient pool and governments to reduce healthcare expenses, could be instrumental in reducing the cost of medication and increasing patient access to treatment.

High cost of monoclonal antibodies

Monoclonal antibodies cost high, both at end-user stage as well as the development stage, primarily owing to the use of highly advanced and expensive facilities.

For the detailed list of factors that will drive and challenge the growth of the monoclonal antibodies market during the 2019-2023, view our report.

Competitive Landscape:

The market appears to be fragmented and with the presence of several companies including Johnson & Johnson and Merck the competitive environment is quite intense. Factors such as the rise in the number of companies venturing into monoclonal antibodies space and the introduction of low cost biosimilar monoclonal antibodies, will provide considerable growth opportunities to monoclonal antibodies manufactures. AbbVie, Amgen, Johnson & Johnson, and Merck are some of the major companies covered in this report.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: PIPELINE ANALYSIS

PART 06: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 08: MARKET SEGMENTATION BY APPLICATION

  • Segmentation by application
  • Comparison by application
  • Oncology - Market size and forecast 2017-2022
  • Immunology - Market size and forecast 2017-2022
  • Hematology - Market size and forecast 2017-2022
  • Others - Market size and forecast 2017-2022
  • Market opportunity by application

PART 09: MARKET SEGMENTATION BY ORIGIN OF MONOCLONAL ANTIBODIES

  • Segmentation by origin of monoclonal antibodies
  • Murine antibodies
  • Human antibodies
  • Humanized antibodies
  • Chimeric antibodies

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 14: MARKET TRENDS

  • Increasing cases of diseases like cancer and immunological disorders
  • Rise in the number of companies venturing into the monoclonal antibodies space
  • Growing pricing pressure in the monoclonal antibodies segment

PART 15: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 16: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie
  • Amgen
  • Johnson & Johnson
  • Merck

PART 17: APPENDIX

  • List of abbreviations
Back to Top